Metilfenidat

Metilfenidat
(IUPAC) ime
	metil fenil(piperidin-2-il)acetat
Klinički podaci
Robne marke	Concerta, Methylin, Ritalin, Equasym XL
AHFS/Drugs.com	Monografija
MedlinePlus	a682188
Identifikatori
CAS broj	113-45-1
ATC kod	N06BA04
PubChem	4158
DrugBank	DB00422
ChemSpider	4015
UNII	207ZZ9QZ49
KEGG	D04999
ChEBI	CHEBI:6887
ChEMBL	CHEMBL796
Hemijski podaci
Formula	C14H19NO2
Mol. masa	233,30 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3 ; Key: DUGOZIWVEXMGBE-UHFFFAOYSA-N
Fizički podaci
Tačka topljenja	214 °C (417 °F)
Farmakokinetički podaci
Bioraspoloživost	~30% (opseg: 11–52%)
Vezivanje za proteine plazme	10-33%
Metabolizam	Hepatički (80%)
Poluvreme eliminacije	3-4 sata (d-enantiomer), 1-3 sata (l-enantiomer)
Izlučivanje	Urin (90%)
Farmakoinformacioni podaci
Licenca	US FDA:link
Trudnoća	B3(AU) C(US)
Pravni status	Droga (S8) (AU) Schedule III (CA) ? (UK) Schedule II (SAD)
Opojna droga	Moderate
Način primene	Oralno, transdermalno

Metilfenidat (Concerta, Methylin, Ritalin, Equasym XL) je psihostimulišući lek i supstituisani fenetilamin koji je odobren tretman hiperkinetičkog poremećaja (ADHD), posturalnog ortostatskog tahikardnog sindroma i narkolepsije. Originalni patent je posedovalo preduzeće CIBA. FDA je odobrila ovaj lek 1955. za tretiranje hiperaktivnosti. Propisivan je od početka 1960-tih. Nivo proskripcija je znatno porastao tokom 1990-tih kad je ADHD dijagnoza postala šire prihvaćena.^[6]^[7]

Reference[uredi - уреди | uredi kôd]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0061%28200004%2917:1%3C48::AID-YEA2%3E3.0.CO;2-H/full.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ When Was Ritalin Invented?, citing Lawrence Diller: "Running on Ritalin", 1999
↑ Lange, K.W. et al.: The history of attention deficit hyperactivity disorder. In: Attention Deficit Hyperactivity Disorders, 2(4):241-55. doi: 10.1007/s12402-010-0045-8.

Literatura[uredi - уреди | uredi kôd]

Gardiner Harris (3. 2. 2012.). „F.D.A. Finds Short Supply of Attention Deficit Drugs”. The New York Times. Arhivirano iz originala 2012-02-03. http://www.nytimes.com/2012/01/01/health/policy/fda-is-finding-attention-drugs-in-short-supply.html?pagewanted=all. Pristupljeno 3. 2. 2012. »(Archived by WebCite® at [1])«
L. Alan Sroufe (28. 1. 2012.). „Ritalin Gone Wrong - Opinion - Children\'s A.D.D.Drugs Don\'t Work Long-Term”. The New York Times. Arhivirano iz originala 2012-02-03. http://www.nytimes.com/2012/01/29/opinion/sunday/childrens-add-drugs-dont-work-long-term.html. Pristupljeno 3. 2. 2012. »(Archived by WebCite® at [2])«
{Cite journal|author=Lakhan SE, Hagger-Johnson GE |title=The impact of prescribed psychotropics on youth |journal=Clin Pract Epidemol Ment Health |volume=3 |page=21 |year=2007 |pmid=17949504 |pmc=2100041 |doi=10.1186/1745-0179-3-21 |url=http://www.cpementalhealth.com/content/3/1/21 |issue=1}}
Drug Enforcement Administration, Greene, S.H., Response to CHADD petition concerning Ritalin, 1995, August 7. Washington, DC: DEA, U.S. Department of Justice.
New Research Helps Explain Ritalin's Low Abuse Potential When Taken As Prescribed – 09/29/1998 Arhivirano 2010-05-28 na Wayback Machine-u. Nih.gov. Retrieved on 2011-04-30.
Weinberg WA, Brumback RA (1992). „The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes”. J. Child Neurol. 7 (4): 431–45; discussion 446–61. DOI:10.1177/088307389200700420. PMID 1469255. http://jcn.sagepub.com/cgi/pdf_extract/7/4/431.
"Are we over medicating our kids? Speaking with Dr. Harold Koplewicz of @ChildMindDotOrg". Presenters: Joan Hamburg and Dr. Harold Koplewicz. Joan Hamburg Show (Radio). WOR Radio Network. WOR, New York, NY. 3. 2. 2012.. 1:11 into the complete two part show - 2 minutes in. Transcript. Arhivirano 2012-12-03 na Wayback Machine-u

</ref>

Spoljašnje veze[uredi - уреди | uredi kôd]

	Portal Medicina
	Portal Hemija

Metilfenidat na Projektu Open Directory
Department of Energy September 29, 1998 press release on Ritalin at Brookhaven National Laboratory
Erowid methylphenidate vault
U.S. National Library of Medicine: Drug Information Portal – Methylphenidate

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0061%28200004%2917:1%3C48::AID-YEA2%3E3.0.CO;2-H/full.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] When Was Ritalin Invented?, citing Lawrence Diller: "Running on Ritalin", 1999

[7] Lange, K.W. et al.: The history of attention deficit hyperactivity disorder. In: Attention Deficit Hyperactivity Disorders, 2(4):241-55. doi: 10.1007/s12402-010-0045-8.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Metilfenidat

Reference[uredi - уреди | uredi kôd]

Literatura[uredi - уреди | uredi kôd]

Spoljašnje veze[uredi - уреди | uredi kôd]

Navigacijski meni